Limits...
Efficacy of 18F-FDG PET/CT in investigation of elevated CEA without known primary malignancy

View Article: PubMed Central - PubMed

ABSTRACT

Aim:: To evaluate the efficacy of 18flurodeoxyglucose positron emission tomography/computer tomography (18F-FDG PET/CT) in investigating patients with elevated carcinoembryonic antigen (CEA) and without known primary malignancy, and the impact of PET/CT findings on patient management.

Setting and design:: PET/CT scans done in a tertiary hospital between December 2007 and February 2012 for elevated CEA in patients without known primary malignancy were retrospectively reviewed.

Materials and methods:: The PET/CT findings, patients' clinical information, level of CEA, histological diagnosis, and subsequent management were retrieved by the electronic patient record for analysis.

Statistical analysis:: Data were analyzed using SPSS version 19.

Results:: One hundred and one PET/CT scans were performed for patients with elevated CEA. Fifty-eight of these were performed for patients with known primary malignancy and were excluded; 43 PET/CT scans were performed for patients without known primary malignancy and were included. Thirty-three (77%) had a positive PET/CT. Among the 32 patients with malignancy, 15 (47%) suffered from lung cancer and 8 (25%) suffered from colorectal cancer. The sensitivity (97%), specificity (82%), positive predictive value (94%), negative predictive value (90%), and accuracy (93%) were calculated. Thirty (91%) patients had resultant change in management. The mean CEA level for patients with malignancy (46.1 ng/ml) was significantly higher than those without malignancy (3.82 ng/ml) (P < 0.05). In predicting the presence of malignancy, a CEA cutoff at 7.55 ng/ml will achieve a sensitivity of 91% and a specificity of 73%.

Conclusion:: PET/CT, in our study population, appears to be sensitive, specific, and accurate in investigating patients with elevated CEA and without known primary malignancy. In addition to diagnosis of underlying primary malignancy, PET/CT also reveals occult metastases which would affect patient treatment options. Its role in investigating patients with elevated CEA and without known primary, compared with other investigation modalities, remains to be studied.

No MeSH data available.


Analysis of 101 patients with elevated CEA
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036343&req=5

Figure 2: Analysis of 101 patients with elevated CEA

Mentions: Between December 2007 and February 2012, there were 101 PET/CT scans performed for patients with elevated CEA. Fifty-eight of these were performed for patients with known primary malignancy and were excluded. Forty-three PET/CT scans were performed for patients without known primary and were included in the analysis [Figure 2]. Their basic demographics are listed in Table 1. The mean time interval between CEA measurement and PET/CT was 13.3 (2–115) days. Some patients had undergone multiple investigations before PET/CT, resulting in a longer time interval. The distribution of CEA level is depicted in Table 2. Because of the time lag between referral and examination, 1 patient had his CEA level normalized (0.6 ng/ml) 3 days before PET/CT.


Efficacy of 18F-FDG PET/CT in investigation of elevated CEA without known primary malignancy
Analysis of 101 patients with elevated CEA
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036343&req=5

Figure 2: Analysis of 101 patients with elevated CEA
Mentions: Between December 2007 and February 2012, there were 101 PET/CT scans performed for patients with elevated CEA. Fifty-eight of these were performed for patients with known primary malignancy and were excluded. Forty-three PET/CT scans were performed for patients without known primary and were included in the analysis [Figure 2]. Their basic demographics are listed in Table 1. The mean time interval between CEA measurement and PET/CT was 13.3 (2–115) days. Some patients had undergone multiple investigations before PET/CT, resulting in a longer time interval. The distribution of CEA level is depicted in Table 2. Because of the time lag between referral and examination, 1 patient had his CEA level normalized (0.6 ng/ml) 3 days before PET/CT.

View Article: PubMed Central - PubMed

ABSTRACT

Aim:: To evaluate the efficacy of 18flurodeoxyglucose positron emission tomography/computer tomography (18F-FDG PET/CT) in investigating patients with elevated carcinoembryonic antigen (CEA) and without known primary malignancy, and the impact of PET/CT findings on patient management.

Setting and design:: PET/CT scans done in a tertiary hospital between December 2007 and February 2012 for elevated CEA in patients without known primary malignancy were retrospectively reviewed.

Materials and methods:: The PET/CT findings, patients' clinical information, level of CEA, histological diagnosis, and subsequent management were retrieved by the electronic patient record for analysis.

Statistical analysis:: Data were analyzed using SPSS version 19.

Results:: One hundred and one PET/CT scans were performed for patients with elevated CEA. Fifty-eight of these were performed for patients with known primary malignancy and were excluded; 43 PET/CT scans were performed for patients without known primary malignancy and were included. Thirty-three (77%) had a positive PET/CT. Among the 32 patients with malignancy, 15 (47%) suffered from lung cancer and 8 (25%) suffered from colorectal cancer. The sensitivity (97%), specificity (82%), positive predictive value (94%), negative predictive value (90%), and accuracy (93%) were calculated. Thirty (91%) patients had resultant change in management. The mean CEA level for patients with malignancy (46.1 ng/ml) was significantly higher than those without malignancy (3.82 ng/ml) (P < 0.05). In predicting the presence of malignancy, a CEA cutoff at 7.55 ng/ml will achieve a sensitivity of 91% and a specificity of 73%.

Conclusion:: PET/CT, in our study population, appears to be sensitive, specific, and accurate in investigating patients with elevated CEA and without known primary malignancy. In addition to diagnosis of underlying primary malignancy, PET/CT also reveals occult metastases which would affect patient treatment options. Its role in investigating patients with elevated CEA and without known primary, compared with other investigation modalities, remains to be studied.

No MeSH data available.